India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.
Source :- mint – markets Read More
- Home
- Livemint Markets
Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full
- No Comments
- 6 Min Read
Share it :
Get free tips and resources right in your inbox, along with 10,000+ others
Categories
Latest Post
